PATENT
Case: OC01000KQ US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	
RYBAK *ET AL.*	Examiner: A. HOLLERAN
For:	Group Art Unit: 1642
MELANOMA THERAPY	
Serial No.: 09/904,263	
Filed: July 12, 2001	

Schering-Plough Corporation
Kenilworth, New Jersey 07033-0530

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION UNDER 37 C.F.R. § 1.132 OF DAVID CUTLER, M.D., FRCPC.

I, Dr. David Cutler, declare and state as follows:

1. I earned an M.D. degree with honors from the University of Saskatchewan in 1982. I completed a rotating internship at North York General Hospital at the University of Toronto in 1983 and an Internal Medicine Residency at the Mayo Clinic in Rochester, Minnesota in 1986. From 1986 to 1988, I underwent Subspeciality Training in Endocrinology and Metabolism at the University of Toronto. I was a Research Fellow at the UCSD Medical Center in San Diego, California from 1988 to 1991. Attached is a copy of my *curriculum vitae* (Exhibit A).

2. Since 1996, I have been employed at Schering-Plough Corporation, the assignee of the present patent application. I am currently Senior Director, Early Clinical Research and Experimental Medicine. At Schering-Plough, I have

supervised clinical trials using Intron (an interferon alpha 2b) and PEG-INTRON (a pegylated interferon alpha 2b).

3. I am familiar with the January 29, 2003, May 20, 2003, and June 29, 2004 Office Actions issued in the above-identified application and with the arguments that have been made by Applicants in the Responses filed February 26, 2003, October 20, 2003 and March 22, 2004 in support of patentability of the pending claims.

I have reviewed the Declaration of Dr. Craig Tendler, which was filed in this application on October 20, 2003, and agree with the points made therein. I understand the Tendler Declaration opined that because pegylation of a given molecule changes both the molecular and pharmacokinetic properties of the molecule, the pegylated and unpegylated versions of the molecules should be considered to be two different drugs (Tendler Declaration ¶ 5). Therefore, using unpegylated interferon alpha to treat melanoma is not predictive of using pegylated interferon alpha to safely and efficaciously treat the disease (Tendler Declaration ¶4). Specifically, Dr. Tendler stated that the relationship of peak plasma levels (Cmax) to total drug exposure (AUC) is different for pegylated interferon alpha compared to that of unpegylated interferon alpha, and that administration of pegylated interferon alpha results in a decreased Cmax and an increased AUC as compared to native interferon (Tendler Declaration ¶6).

4. I am aware that in the Office Action dated June 29, 2004, the Examiner questions whether a decrease in peak plasma levels due to pegylation of interferon alpha is true for all forms of pegylated interferon alpha (Office Action p. 3).

5. I make this Declaration to supplement the submission of data that supports the conclusion that <u>at the doses defined by the pending claims to treat melanoma</u>, administration of <u>PEG_{12000}</u> interferon alpha resulted in lower peak plasma levels of interferon alpha activity but prolonged total drug exposure as compared to administration of unconjugated interferon alpha.

6. Table 1, below, contains pharmacokinetic data indicating that at the doses used to treat melanoma in humans (25 MIU for Interferon alpha and 3 µg/kg for PEG_{12000}-interferon alpha), the C_{max} is significantly lower when the pegylated version of interferon alpha was administered than when the unconjugated version was administered. Data presented below are plasma concentrations of bioactive interferon measured in a bioassay and reported as international units (IU/mL). These data are extracted from a multiple dose safety and tolerability study of several dose levels of PEG Intron and Intron A. Post hoc determination of the Cmax and AUC are presented. The data from the highest dose of PEG Intron, 2 µg/kg are normalized to a clinical dose of 3 µg/kg. Similarly, the date from the Intron A treatments at 3 MIU are normalized to a clinical dose of 25 MIU.

Table 1.

Individual and Mean Cmax

PEG 2 µg/kg Wk 4	Intron 3 MIU Wk 4
300	38
150	28
94	38
113	19
150	19
225	14
	47
	56
	23
	38
	94
	300
	75
	75
	56
	38
Mean	**Mean**
172	**59.875**
Normalized Mean	**Normalized Mean**
258	**479**

7. Table 2, below, contains data generated in the same study. This table shows that the total drug exposure (AUC) was higher in patients in which PEG_{12000} interferon alpha was administered compared to those in which comparable doses of native interferon alpha was administered. Data are again normalized to the clinical doses of 3 µg/kg for PEG Intron and to 25 MIU for Intron A. Data for PEG Intron are calculated to 7 days, while data for Intron are truncated at 48 hours.

Table 2

Individual and Mean AUC

PEG 2 µg/kg Wk 4	Intron 3 MIU Wk 4
1578	907
2230	541
8703	1110
8006	353
9538	437
24468	242
	1584
	1295
	711
	806
	1594
	3685
	2452
	1642
	2767
	1420
Mean	**Mean**
13116	**1347**
Normalized Mean	**Normalized Mean**
19673	**11217**

8. Therefore, I am of the opinion that at the doses used to treat melanoma, administration of PEG_{12000} interferon alpha resulted in lower peak plasma levels of interferon alpha activity but prolonged total drug exposure as compared to administration of unconjugated interferon alpha.

9. All statements made herein of my own knowledge are true and all statements made on information and belief are believed to be true; and further these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application and any patent issued thereon.

Dec 22, 2004.
Date

David Cutler, M.D., FRCP(C)

Latest revision: 8/11/04

CURRICULUM VITAE

David Lawrence Cutler, M.D., FRCPC

CURRENT ADDRESS:
Schering-Plough Research Institute
2015 Galloping Hill Road
Kenilworth, New Jersey 07033
Telephone: (908) 740-2194
Fax: (908) 740-2169
E-mail: david.cutler@spcorp.com

EDUCATION:

1988 - 1991	Research Fellow UCSD Medical Center San Diego, CA Supervisor: Dr. O. Kolterman
1986 - 1988	Subspeciality Training in Endocrinology and Metabolism University of Toronto Toronto, Ontario
1983 - 1986	Internal Medicine Residency Mayo Clinic Rochester, MN
1982 - 1983	Rotating Internship North York General Hospital University of Toronto Toronto, Ontario
1982	University of Saskatchewan M.D., Magna Cum Laude
1976	University of Saskatchewan Major: Microbiology
1975	University of Regina

LANGUAGES: English

HONORS AND AWARDS :

1979	Graduate scholarship for academic excellence
1978	Graduate scholarship for academic excellence
1977	Graduate scholarship for academic excellence
1976	Undergraduate scholarship for academic excellence
1975	Undergraduate scholarship for academic excellence

CURRENT LICENSURE/CERTIFICATION:

1991-Present	State of New Jersey - MA 57335
1987-Present	State of California - G062988
1983-1987	State of Minnesota
1982-Present	Ontario College of Physicians and Surgeons - 50315
1989	Diplomate American Board of Endocrinology and Metabolism
1988	Fellow of the Royal College of Physicians and Surgeons of Canada F.R.C.P.(C)
1986	Diplomate American Board of Internal Medicine
1985	Diplomate National Board of Medical Examiners
1983	Licentiate Medical Council of Canada (L.M.C.C.)

ACADEMIC/HOSPITAL APPOINTMENTS: None

COMMITTEES/SOCIETIES/PROFESSIONAL AFFILIATIONS::

Fellow	Royal College of Physicians and Surgeons of Canada
Member	American College of Physicians
Member	American Diabetes Association
Member	American Society for Clinical Pharmacology and Therapeutics
1998-2002	Reviewer - Annals of Pharmacotherapy
1997-2002	Member - Robert Wood Johnson Medical Center - Clinical Research Center Advisory Board
3/88-6/88	Chief endocrine resident St. Michael's Hospital, Toronto, Ontario, Canada
7/87-12/87	Chief endocrine resident Wellesley Hospital, Toronto, Ontario, Canada
1/87-6/87	Chief endocrine resident Toronto General Hospital, Toronto, Ontario, Canada
7/86-12/86	Chief endocrine resident Mount Sinai Hospital, Toronto, Ontario, Canada

WORK EXPERIENCE:

2002-Present	Senior Director Early Clinical Research and Experimental Medicine Schering-Plough Research Institute
2001-2002	Senior Director Clinical Pharmacology Schering-Plough Research Institute
1998 - 2001	Director Clinical Pharmacology Schering-Plough Research Institute
1996 - 1998	Senior Clinical Research Physician Clinical Pharmacology Schering-Plough Research Institute

1994 - 1996 Senior Associate Director
Clinical Pharmacology
Schering-Plough Research Institute

1991 - 1994 Associate Director
Clinical Pharmacology
Schering-Plough Research Institute

PATENTS

5,908,621 - Polyethylene glycol modified interferon therapy
5,945,097 - Method for lowering cholesterol levels with Interleukin-10
6,096,757 - Method for treating proliferative diseases
6,117,074 - Polyethylene glycol modified interferon therapy
6,333,333 - Method for treating proliferative diseases
6,461,605 - B1- Continuous low-dose cytokine infusion therapy
6,524,570 – B1- Polyethylene Glycol Modified Interferon Therapy

PUBLICATIONS/PRESENTATIONS:

Presentations:

1. Freidenberg, G., Jones, M., Hall, B., **Cutler, D.**, Kaufmann, S.: A new syndrome of insulin resistance diabetes mellitus and mandibuloacral dysplasia. Western Society of Pediatric Research, Carmel, CA, 1989.

2. **Cutler, D.L.**, Park, S.W., Hanchett, C., Hickman, M., Bell, J., Gray, G., Kolterman, O.: Low carbohydrate diet does not cause insulin resistance in exercise-trained subjects. American Diabetes Association Annual Meeting, Atlanta, Georgia, 1990.

3. Park, S., **Cutler, D.**, Crone, L., Bell, J., Verity, L., Kolterman, O.: Insulin and exercise interact synergistically to activate glycogen synthase. American Diabetes Association Annual Meeting, Atlanta, Georgia, 1990.

4. **Cutler, D.L.**, Kolterman, O.G., Hintz, R.L., Prince, M.J. Tumor associated hypoglycemia: IGF-I and II prohormone associated augmentation of glucose oxidation. Western Section AFCR, Carmel, CA, 1991.

5. Pajkrt, D., **Cutler, D.**, Grint, P., Tiel, M., van Deventer, S.J.H. Recombinant human IL-10 (rhuIL-10) reduces cytokine release and granulocyte recruitment in lungs in human endotoxemia. 36th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 15-18, 1996, New Orleans, Louisiana, (Abstract G32): 149, 1996.

6. Haehner-Daniels, B.D., **Cutler, D.L.**, Affrime, M.B., Gorski, J.C., Hall, S.D. The selective in vivo increase of cytochrome P450 2C8/9 activity by interleukin-10 (IL-10). 99th American Society for Clinical Pharmacology and Therapeutics, March 30 - April 1, 1998, New Orleans, Louisiana.

7. Radwanski, E., Chakraborty, A., VanWart, S., **Cutler, D.L.**, Affrime, M.B., Jusko, W.J. Pharmacokinetics and dynamics (cytokine suppression) of IV and SC recombinant human interleukin-10. 99th American Society for Clinical Pharmacology and Therapeutics, March 30 - April 1, 1998, New Orleans, Louisiana.

ABSTRACTS

1. Freidenberg, G., Jones, M., Hall, B., **Cutler, D.**, Kaufmann, S.: A new syndrome of insulin resistance diabetes mellitus and mandibuloacral dysplasia. Clinical Research, 37(1), p192A, 1989.

2. **Cutler, D.L.**, Park, S.W., Hanchett, C., Hickman, M., Bell, J., Gray, G., Kolterman, O.: Low carbohydrate diet does not cause insulin resistance in exercise-trained subjects. Diabetes, 39;Supp. (1), p.64A, 1990.

3. Park, D., **Cutler, D.**, Crone, L., Bell, J., Verity, L., Kolterman, O.: Insulin and exercise interact synergistically to activate glycogen synthase. Diabetes, 39;Supp.(1), p13A, 1990.

4. **Cutler, D.L.**, Kolterman, O.G., Hintz, R.L., Prince, M.J. Tumor associated hypoglycemia: IGF-I and II prohormone associated augmentation of glucose oxidation. Clinical Research 39;1, 101A, 1991.

5. Freidenberg, G., **Cutler, D.**: Insulin resistance, diabetes mellitus and mandibuloacral dysplasia. Proc 71st Endocrine Society Abstract 150.

6. Prince, M.J., Kolterman, O.G., **Cutler, D.L.**: Predominant augmentation of glucose oxidation in tumor associated hypoglycemia. Diabetes 40;(Supp 1):100A, 1991.

7. **Cutler, D.L.**, Kolterman, O.G.: Vanadate increases pyruvate dehydrogenase activity in diabetic rats. Diabetes 40;(Supp 1):261(A), 1991.

8. Freidenberg, G., Kushari, J., **Cutler, D.**: A case of diabetes mellitus and insulin resistance: result of defects in the insulin receptor. Diabetes 40;(Supp 1):113A, 1991.

9. Crone, L.L., Verity, L.S., **Cutler, D.L.**, Kolterman, O.G., Nichols, F.N.: (Effect of) acute exercise on glucose disposal in well and poorly controlled Type I diabetics v normals. Medicine and Science in Sports and Exercise 23;4 (Supp):S100, 1991.

10. **Cutler, D.L.**, Park, S.W., Hanchett, K., Hickman, M., Bell, J.M., Gray, C., Kolterman, O.G.: Interactions between exercise training and carbohydrate restriction. Clinical Research 38;1, 118A, 1990.

11. Macherone, A., Batra, V., Lin, C., Korduba, C., Affrime, M., Teal, M., **Cutler, D.**, Radwanski, E.: Comparison of the pharmacokinetics of isepamicin in young and geriatric volunteers. Pharmaceutical Research 10;10:Suppl, 317, 1993.

12. Radwanski, E, Nomeir, A, **Cutler, D.**, Fettner, S., Lin, C., Affrime, M., Batra, V. Pharmacokinetics of ceftibuten administered with and without Mylanta II or ranitidine. Pharmaceutical Research 10;10:Suppl, 310, 1993.

13. Swan, S.K., Radwanski, E., **Cutler, D.**, Affrime, M., Scott, M., Halstenson, C.: Pharmacokinetics of flutamide (F) in patients with renal insufficiency (RI). Clinical Pharmacology and Therapeutics 55;2:207, 1994.

14. Radwanski, E., Macherone, A., **Cutler, D.**, Huhn, R., Affrime, M., Jacobs, S., Cayen, M.N., Batra, V.K.: Rising single-dose safety and tolerance of IL-10 in normal male volunteers. Pharmaceutical Research 11;10:Suppl, 339, 1994.

15. Pai, S., Zhu, G.R.R., **Cutler, D.**, Cayen, M., Batra, V.: A population pharmacokinetic approach in prospectively designing a sampling scheme for phase II/III trials of temozolomide. Pharmaceutical Research 11;10:Suppl, 410, 1994.

16. **Cutler, D.L.**, Kosoglou, T., Alton, K.B., Sabo, R., Patrick, J.E., Batra, V.J., Nezamis, J., Affrime, M.B.: Effect of a high-fat vs. non-fat meal on the bioavailability (BA) of SCH 48461. Clinical Pharmacology and Therapeutics 57;2:173, 1995.

17. Huhn, R.D., O'Connell, S.M., Radwanski, E., **Cutler, D.L.**, Sturgill, M., Clarke, L., Seibold, J.R.: Phase I pharmacodynamic study of intravenous (IV) recombinant human interleukin-10 (RHIL-10) in normal volunteers. Clinical Pharmacology and Therapeutics 57;2:162, 1995.

18. Monge, A., Radwanski, E., **Cutler, D.**, Dinarello, C., Affrime, M., Jacobs, S., Cayen, MN., Batra, V. Effects of intravenously administered IL-10 on parameters of immune function in healthy volunteers. Pharmaceutical Research 12;9:Suppl; 412, 1995.

19. Krumpe, P., Colucci, R., **Cutler, D.**, Lin, C., Korduba, C., Cayen, M., Affrime, M. Lung and chest tissue penetration of isepamicin in patients undergoing lung resection or bronchoscopy. Can J Infect Dis 6:Suppl C;281, 1995.

20. Pai, S., Zhu, G., Colucci, R., **Cutler, D.**, Affrime, M., Cayen, M., Batra, V. Isepamicin dosage regimen estimation in patients with renal dysfunction using a population pharmacokinetic approach. Can J Infect Dis 6: Suppl C;429, 1995.

21. **Cutler, D.L.**, Kosoglou, T., Sabo, R., Affrime, M., Katz, A., Ginsberg, H.: Effect of SCH 48461 on oral cholesterol absorption. Clinical Pharmacology and Therapeutics 59;2:194, 1996.

22. Kosoglou, T., Mojaverian, P., Radwanski, E., Christopher, D., **Cutler, D.**, Lin, C., Affrime, M. Effect of food and postprandal state on the bioavailability of micronized progesterone. Clinical Pharmacology and Therapeutics 59;2:194, 1996.

23. Brannan, M.D., Seiberling, M., **Cutler, D.**, Cuss, F.M., Affrime, M.B. Lack of systemic activity with intranasal mometasone furoate. J Allergy Clin Immunol, 97;1 (part 3):198, January 1996.

24. Glue, P., **Cutler, D.**, Sabo, R., Huhn, R., Witt, P., Jacobs, S., Batra, V., Affrime, M. Pharmacodynamic effects of interferon alfa-2b in healthy volunteers. Clinical Pharmacology and Therapeutics 59;2:205, 1996.

25. Reidenberg, P., Statkevich, P., Judson, I., Moore, S., **Cutler, D.**, Batra, V., Dugan, M., Brada, M. Effect of food on the oral bioavailability of temozolomide, a new chemotherapeutic agent. Clinical Pharmacology and Therapeutics 59;2:199, 1996.

26. Huhn, R.D., Pennline, K., Sabo, R., Clarke, L., Affrime, M.B., **Cutler, D.L.** Effects of single intravenous (IV) doses of recombinant human interleukin-10 (rhIL-10) on subsets of blood leukocytes in healthy volunteers. J Inv Med 44, 275A, 1996.

27. Habet, K., Bunnell, E., **Cutler, D.**, Rapnikas, P., Affrime, M.B., Parrillo, J.E. Modulation of the Systemic Inflammatory Response Syndrome with Interleukin-10 in Human Experimental Endotoxemia. Chest 110, 18S, 1996.

28. Statkevich, P., Judson, I., **Cutler, D.**, Dugan, M., Salfi, M., Batra, V., Reidenberg, P. Effect of Ranitidine® on the Pharmacokinetics (PK) of Temozolomide (T). Clinical Pharmacology and Therapeutics 61; 2:147, 1997.

29. Baker, S.D., Wirth, M., Statkevich, P., Reidenberg, P., Sartonrius, S., Dugan, M., **Cutler, D.**, Batra, V., Rowinsky, E. Absorption, Metabolism, and Excretion of ^{14}C-Temzolomide in Patients with Advanced Cancer. Proceedings of ASCO: 16; 214a, 1997.

30. Lambrecht, L.J., Swan, S.K., **Cutler, D.L.**, Affrime, M.B., Radwanski, E., Batra, V., Macres, M. Disposition of Recombinant Human Interleukin 10 (IL-10) in Patients with Various Degrees of Renal Function. Clinical Pharmacology and Therapeutics 61; 2:216, 1997.

31. Bunnell, E., Habet, K., **Cutler, D.**, Orencole, S., Affrime, M.B., Dinarello, C., Parrillo, J.E. Inhibition of Pro-Inflammatory Cytokines by Interleukin-10 in Human Experimental Endotoxemia. American Thoracic Society 1997 Meeting.

32. **Cutler, D.L.**, Affrime, M.B., Herron, J., Sabo, R. Recombinant Human IL-10 (rHuIL-10) Inhibits Delayed Type Hypersensitivity Response (DTH) in Healthy Volunteers. Clinical Pharmacology and Therapeutics 61; 2:160, 1997.

33. Huhn, R.D., Pennline, K., Radwanski, E., Clarke, L., Sabo, R., Affrime, M., **Cutler, D.L.** Recombinant Human Interleukin-10 (rhIL-10) - Safety, Pharmacodynamics and Immunohematologic Effects of Repeated Daily Subcutaneous (S.C.) Doses in Healthy Volunteers. American Society for Hematology 1997 Meeting.

34. Radwanski, E., Chakraborty, A., VanWart, S., **Cutler, D.L.**, Affrime, M.B., Jusko, W.J. Pharmacokinetics and Dynamics (Cytokine Suppression) of IV and SC Recombinant Human Interleukin-10. Clinical Pharmacology and Therapeutics 63; 2:240, 1998.

35. Gorski, J.C., Haehner, B.D., **Cutler, D.**, Affrime, M.B., Hall, S.D. Lack of Correlation Between Intravenous Midazolam and Oral Dextromethorphan CYP3A Phenotypes. Clinical Pharmacology and Therapeutics 63; 2:150, 1998.

36. Haehner-Daniels, B.D., **Cutler, D.L.**, Affrime, M.B., Gorski, J.C., Hall, S.D. The Selective In Vivo Induction of Cytochrome P450 2C8/9 by Interleukin-10 (IL-10). Clinical Pharmacology and Therapeutics 63; 2:241, 1998.

37. Chakraborty, A., Blum RA., Mis, SM, **Cutler, D.L.**, Jusko, WJ. Pharmacokinetic – Pharmacodynamic Interaction IL-10 and Prednisone in Normal Volunteers. AAPS Pharm Sci 1(1) Suppl. (Abstract 3806), 1998.

38. Ahrendt, L.D., Witek, J., Dean, L.M., Sigler, A.J., Blumberg, E.A., Wood, C.A., Molavi, A., Mastoridis, P., Affrime, M.B., **Cutler, D.L.**, Gold, M.J., Fuchs, A.C. A Phase I Study of Interleukin-10 (IL-10) in HIV-infected Individuals. 5th Conference on Retroviruses and Opportunistic Infections, 1998.

39. Sosman, J.A., Verma, A., Moss, S.T., Sorokin, P., Blend, M., Bradlow, B., **Cutler, D.**, Sabo, R., Viana, M., Bruno, E., Hoffman, R. The Mechanism of Interleukin-10(rhuIL-10) Induced Thrombocytopenia. ASH 40th Annual Meeting, Miami Beach, Florida, 1998

40. Adjei, A.A., Erlichman, C., Davis, J.N., Reid, Joel, Sloan, J., Statkevich, P., Zhu, Y., Marks, R., Pitot, H., Goldberg, R., Hanson, L., Alberts, S., **Cutler, D.**, Kaufmann, S. A Phase I and Pharmacologic Study of the Farnesyl Protein Transferase (FPT) Inhibitor 66336 in Patients with Locally Advanced Metastatic Cancer. Proceedings of ASCO Volume 18 156a, 1999.

41. Hurwitz, H., Colvin, M., Petros, W.P., Williams, R., Conway, D., Adams, D. J., Casey, P.J., Calzetta, A., Mastorides, P., Statkevich, P., **Cutler, D.**, Phase I and Pharmacodynamic Study of 66336, a Novel FPTI, Using a 2-Week on, 2-week off Schedule. Proceedings of ASCO Volume 18 156a, 1999.

42. Eskens, F., Awada, A., Verweij, J., **Cutler, D.**, Haunauske, A., Piccart, M. Phase I and Pharmacologic Study of Continuous Daily Oral SCH 66336, a Novel Farnesyl Transferase Inhibitor, in Patients with Solid Tumors. Proceedings of ASCO Volume 18 156a, 1999.

43. Awada, A., Eskens F., Piccart, MJ., Van der Gaast, A., Bleiberg, H., **Cutler, D.L.**, Fumoleau, P., Wanders, J., Faber, MN., Verweij, J., A Clinical, Pharmacodynamic and Pharmacokinetic Phase I Study of SCH 66336 (SCH) an Oral Inhibitor of the Enzyme Farnesyl Transferase given once Daily in Patients with Solid Tumors. Proceedings AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Theropeutics. 5, 1999.

44. Denis, L., Tolcher, A., Figueroa, J., Drengler, R., Geyer, C., Eckhardt, SG., **Cutler, D.**, Reyderman, L., Von Hoff, D., and Rowinsky, E. Protracted Daily Administration of Temozolomide is Feasible; A Phase I and Pharmacokinetic/Pharmacodynamic Study. Proceedings of ASCO 19:202,2000.

45. Figueroa, J., Tolcher, A., Denis, LJ., Drengler, R., Geyer, C., Eckhardt, SG., **Cutler, D.**, Reyderman, L., Von Hoff, D., and Rowinsky, E. Protracted Cyclic Administration of Temozolomide is Feasible; A Phase I, Pharmacokinetic and Pharmacodynamic Study. Proceedings of ASCO 19:222, 2000.

46. Tolcher, A., Felton, S., Gerson, S.L., Edwards, T., Patnaik, A., Smith, L., Geyer, C., Johnson, T., Reyderman, L., **Cutler, D.**, Rowinsky, E. Persistent and Marked Inactivation

of O^6-Alkylguanine-DNA Alkytransferase Activity (AGAT), A Mechanism of Resistance to Alkylators, with Protracted Low-Dose Oral Schedules of Temozolamide. Proceedings of ASCO 19:175,2000.

47. Hurwitz, H., Amado, R., Prager. D., Hecht, J., Cohen, D., Conway, D., Kadib, L., Mayers, A., Calzetta, A., Statkevich, P., **Cutler, D.**, and Rosen, L. Phase I Pharmacokinetic Trial of the Farnesyl Transferase Inhibitor Sch 66336 Plus Gemcitabine in Advanced Cancers. Proceedings of ASCO 19:185,2002.

48. Kosoglou, T., Meyer, I., **Cutler, D.**, Musiol, B., Yang, B., Zhu, Y., Maxwell, S., Affrime, M., Veltri, E. Pharmacodynamic Interaction Between the Selective Cholesterol Absorption Inhibitor Ezetimibe and Lovastatin. International Congress on Coronary Artery Disease, Abstract book 3:101 (Abstract 390), 2000

49. Kosoglou, T., Meyer, I., Musiol, B., **Cutler, D.**, Yang, B., Veltri, E., Affrime, M. Coadministration of Simvastatin and Ezetimibe Leads to Significant Reduction in LDL-Cholesterol. International Congress on Coronary Artery Disease, Abstract book 3:71 (Abstract 275), 2000

50. Kosoglou, T., Statkevich, P., Bauer, K., **Cutler, DL.**, Maxwell, SE., Yang, B., Soni, P., Batra, V. Ezetimibe dose not affect the Pharmacokinetics and Pharmacodynamics of Digoxin. AAPS Pharm. Sci. 3(3) supp., 2001

51. Statkevich, P., Reyderman, L., Kosoglou, T., Woloj, M., Maxwell, SE., **Cutler, DL.**, Batra, V., Kleinermans, D. Ezetimibe Dose not affect the Pharmacokinetics and Pharmacodynamics of Glipizide. Clin. Pharm. Ther 69(2):67, 2001.

52. Keung, AC., Kosoglou, T., Statkevich, P., Anderson, L., Boutros, T., **Cutler, D.L**, Batra, V., Sellers, EM. Ezetimibe dose not affect the Pharmacokinetics of Oral Contraceptives. Clin. Pharm. Ther 69(2):55, 2001.

53. Jen, F., **Cutler, D.**, Pai, S., Batra, V., Affrime, M., Zambas, D., Heft, S., Hajian, G. Population Pharmcokinetics of Temozolomide in Cancer Patients.

54. Kosoglou, T., Guillaume, M., Sun, S., Pember, L., Reyderman, L., Statkevich, P., **Cutler, D.**, Veltri, E., Affrime, M. Pharmacodynamic Interaction Between Fenofibrate and the Cholesterol Absorption Inhibitor Ezetimibe. Atherosclerosis Suppl 2 (2):38, 2001

55. Sprague, E., Vokes, EE., Garland, LL., McCage, M., O'Neill, S., **Cutler, D.**, Von Hoff, D. Phase I Study of continuous Lonafarnib plus Paclitaxel and Carboplatin. Proceedings of ASCO. 21(2) (Abstract 1920), 28b 2002.

56. Kosoglou, T., Seiberling, M., Statkevich, P., **Cutler, Dl.**, Yang, B., Anderson, L., Maxwell, SE. Affrime, M. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and atorvastatin. J. Am. Coll. Cardiol. 37 (2) Supp. A, 229A, 2001.

57. Zhu, Y., Statkevich, P., **Cutler, D.**, Pember, L., Curtis, D., Batra, V. Effect of Food on the Pharmacokinetics of Lonafarnib, a Farnesyl Protein transferase inhibitor. Clin. Pharm. Ther. 71:2, 82, 2002.

58. de Bono, J., Denis, L. Patnaik, A., Hammond, L., Geyer, C., Gerson, S., **Cutler, D.**, Reyderman, L., Rowinsky, E. Tolcher, A. Extended Temozolomide (TMZ) dosing schedules permit the administration of higher TMZ dose intensities and inhibit the DNA repair enzyme 0^6-Alkylguanine DNA Alkyltranserase. Eur. J. Cancer 37(6) S31-S32, 2001.

59. Chakraborty, A., Radwanski, E., Van Wart, S, **Cutler, D.J**, Affrime, M., Jusko, W. Pharmacokinetic Modeling of Subcutaneously Administered Macromolecules -Application to Recombinant Human Interleukin 10. Pharmaceutical Research 14. S-615, 1997.

60. Awada, A., Dubuisson, M., Sales, F., Vereecken, P., Gil, T., **Cutler, D.**, Moerman, C., Branle, F., Lehmann, F., Klastersky, J., de Valeriola D., Piccart, M. A Phase I Study of a prolonged schedule of Temozolomide (Temodar) Plus Liposomal Doxorubicin (Caelyx) in Advance Solid Cancers: Final results of a promising combination. Proceedings of ASCO Volume 21 (2) (Abstract 2130), 2002

61. Kosoglou, T., Meyer, I., Musiol, B., Anderson, L., Reyderman, L., Statkevich, P., **Cutler, D.**, Veltri, E.P., Affrime, M.B., Pharmacodynamic Interaction Between Fluvastatin and Ezetimibe has Favorable Clinical Implications. Atherosclerosis 2 Suppl 2:89,2001

62. Jen, F., **Cutler, D.**, Gupta, S., Hajian G., Population Pharmacokinetic Analysis of Pegylated Interferon Alfa-2b (Peg-Intron) in Patients with Chronic Myelogenous Leukemia. AAPS Pharmsci, Supp 3 (3) 2001

63. Zhu Y, Statkevich P, **Cutler DL**, Calzetta A, Curtis D and Batra VK. Lonafarnib, A Farnesyl Protein Transferase Inhibitor, Does Not Affect the Pharmacokinetics of Gemcitabine. AAPS Pharmsci 4 (Supp 4), 2002

64. Reyderman L, Statkevich P, **Cutler DL**, Boutros T, Maxwell SE and Batra VK. Rising Multiple-Dose Pharmacokinetics of Acolbifene in Combination with Estradiol. AAPS Pharmsci 4 (Supp 4), 2002.

65. Courtney RD, **Cutler DL**, Belanger A, Sabo R, Batra VK and Statkevich P. Effect of Food on the Pharmacokinetics of Estradiol in Postmenopausal Women. AAPS Pharmsci 4 (Supp 4), 2002.

66. Zhu Y, Statkevich P, **Cutler DL**, Calzetta A, Rosen L, Curtis D, Batra VK. Reduced Effect of Food on the Pharmacokinetics of Lonafarnib Following Multiple Oral Doses. Submitted for presentation at the 2003 Clin Pharm Ther 73(2):67, 2003.

67. Zhu Y, Statkevich P, Curtis D, **Cutler DL**, Zhang M, Richards W and Batra VK. Effects of Age and Gender on the Pharmacokinetics of Lonafarnib (L) Following a Single Oral Dose. Clinical Pharmacology & Therapeutics, Volume 75 (2):2004

68. Zhu Y, Statkevich P, **Cutler DL**, Calzetta A, Curtis D and Batra VK. Pharmacokinetics (PK) of Lonafarnib (L), A Farnesyl Proten Transferase Inhibitor. Clinical Pharmacology & Therapeutics, Volume 75 (2):2004

69. Kosoglou T, Statkevich P, Reyderman L, Pember LJC, Maxwell SE, Courtney R, Krishna G and **Cutler DL**. Effects of selected drugs on exposure to ezetimibe. European Heart Journal Volume 24 2003.

70. Kosoglou T, Statkevich P, Yang B, Suresh R, Yali Z, Maxwell S, Tiessen R, **Cutler DL.** Pharmacodynamic Interaction Between Ezetimibe and Rosuvastatin. American College of Cardiology.

POSTERS

1. Freidenberg, G., **Cutler, D.**: Insulin resistance, diabetes mellitus and mandibuloacral dysplasia. Endocrine Society 71st Annual Meeting, Seattle, Washington.

2. Prince, M.J., Kolterman, O.G., **Cutler, D.L.**: Predominant augmentation of glucose oxidation in tumor associated hypoglycemia. IDF Congress, Washington, DC, 1991. Diabetes 40;(Supp 1):100A, 1991.

3. **Cutler, D.L.**, Kolterman, O.G.: Vanadate increases pyruvate dehydrogenase activity in diabetic rats. IDF Congress, Washington, DC, 1991. Diabetes 40;(Supp 1):261(A), 1991.

4. Freidenberg, G., Kushari, J., **Cutler, D.**: A case of diabetes mellitus and insulin resistance: result of defects in the insulin receptor. IDF Congress, Washington, DC, 1991. Diabetes 40;(Supp 1):113A, 1991.

5. Crone, L.L., Verity, L.S., **Cutler, D.L.**, Kolterman, O.G., Nichols, F.N.: (Effect of) acute exercise on glucose disposal in well and poorly controlled Type I diabetics v normals. ASCM Annual Meeting, Orlando, Florida, 1991. Medicine and Science in Sports and Exercise 23;4 (Supp):S100, 1991.

6. Nomeir, A., Korduba, C., Radwanski, E., Batra, V., **Cutler, D.**, Affrime, M., Cayen, M., Lin, C. Single dose pharmacokinetics of isepamicin in the young and geriatric volunteers. 35th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) , P21 (Abstract A112), September 17-20, 1995, San Francisco, California.

7. Scaglione, F., Vigano, A., Colucci, R., Zampaglione, N., Lin, C., **Cutler, D.**, Guerciolini, R., Elliott, M., Affrime, M., Radwanski, E. Pharmacokinetics of isepamicin in pediatric patients. 35th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) September 17-20, 1995, San Francisco, California.

8. Huhn, R.D., **Cutler, D.L.**, Radwanski, E., Gonyo, G., Affrime, M.B. Pharmacodynamics of subcutaneous recombinant human interleukin-10 (rhIL-10) in normal human volunteers: prolonged inhibition of ex vivo endotoxin-stimulated whole blood cytokine synthesis. American Association of Cancer Research Conference on Cytokines and Cytokine Receptors October 14-18, 1995, Bolton Landing, New York.

9. Huhn, R.D., Pennline, K., Sabo, R., Clarke, L., Affrime, M.B., **Cutler, D.L.** Effects of single intravenous (IV) doses of recombinant human interleukin-10 (rhIL-10) on subsets of blood leukocytes in healthy volunteers. Annual Retreat on Cancer Research in New Jersey, 1996.

10. Jen, J.F., **Cutler, D.**, Pai, S., Batra, V., Affrime, M., Hajian, G., Heft, S. Population Pharmacokinetic Analysis of Temozolomide. Conference for the Population Approach Meeting February 12-14, 1997, Geneva Switzerland.

11. Vokes E, Sprague E, Ratain M, Garland L, McCabe M, Von Hoff D, Zhu Y, Statkevich P, O'Neill S, **Cutler DL**. Continuous Sarasar (Lonafarnib) Plus Carboplatin and Paclitaxel: A Phase I Study in Advanced or Refractory Solid Tumors. Third International Lung Cancer Congress, Hawaii, June 2002.

MANUSCRIPTS

1. Freidenberg, G., **Cutler, D.**, Jones, M., Hall, B., Mier, R., Culler, F., Jones, K., Lozzio, C.: Severe insulin resistance and diabetes mellitus in mandibuloacral dysplasia. Am J Dis Child 146:93-99, 1992.

2. **Cutler, D.**, Kaufmann, D., Freidenberg, G.: Insulin resistant diabetes mellitus and hypermetabolism in mandibuloacral dysplasia: a newly recognized form of partial lipodystrophy. J Clin Endo Metab 73;5:1056-1061, 1991.

3. **Cutler, D.L.**, Park S.W., Hickman, M.G., Bell, J.M., Gray, C.G., Kolterman, O.G.: Low carbohydrate diet alters intracellular glucose metabolism but not overall glucose disposal in exercise-trained subjects. Metabolism: Clinical and Experimental 44;10:1264-1270, 1995.

4. Gray, C.G., Kolterman, O.G., **Cutler, D.L.**: The effects of a three week adaption to a low carbohydrate/high fat diet on metabolism and cognitive performance. U.S. Naval Medical Research and Development Command Report No. 90-20, 1990.

5. Aweeka, F.T., Mak, M., Al-Uzri, A., Peter, K., Dett, C., Franco, J., Affrime, M., Guerciolini, R., **Cutler, D.L.**, Kahn, J., Gambertoglio, J.G.: Oral and intravenous zidovudine pharmacokinetics: the effect of granulocyte-macrophage colony stimulating factor. J Clin Pharmacol 35:856-864, 1995.

6. Huhn, R.D., Radwanski, E., O'Connell, S.M., Sturgill, M.G., Clarke, L., Cody, R.P., Affrime, M.B., **Cutler, D.L.**: Pharmacokinetics and immunomodulatory properties of intravenous recombinant human interleukin-10 in healthy volunteers. Blood, 87:699-705, 1996.

7. Fuchs, A.C., Granowitz, E.V., Shapiro, L., Vannier, E., Lonnemann, G., Angel, J.B., Kennedy, J.S., Rabson, A.R., Radwanski, E., Affrime, M.B., **Cutler, D.L.**, Grint, P., Dinarello, C.A.: Clinical, hematologic and immunologic effects of interleukin-10 in humans. Journal of Clinical Immunology, 16;5: 291-303, 1996.

8. Barr, W.H., Colucci, R., Radwanski, E., Zampaglione, N., **Cutler, D.L.**, Affrime, M.B.: Pharmacokinetics of isepamicin. Journal of Chemotherapy 7;Supp 2:53-61, 1995.

9. Scaglione, F., Vigan, A., Colucci, R., Zampaglione, N., Lin, C., Elliott, M., **Cutler, D.**, Affrime, M., Radwanski, E.: Pharmacokinetics of isepamicin in pediatric patients. Journal of Chemotherapy 7;Supp 2:63-69, 1995.

10. Lin, C., Korduba, C., Affrime, M., Radwanski, E., Nomeir, A., Batra, V., **Cutler, D.**, Cayen, M.N.: Pharmacokinetics and metabolism of ^{14}C-isepamicin in humans following intravenous administration. Antimicrobial Agents and Chemotherapy 39; 10:2201-2203, Oct. 1995.

11. Pajkrt, D., Camoglio, L., Tiel-van Buul, M.C.M., de Bruin, K., **Cutler, D.L.**, Affrime, M.B., Rikken, G., van der Poll, T., Wouter ten Cate, J., van Deventer, S.J.H. Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: the effect of timing of recombinant IL-10 administration. Journal of Immunology 158; 8: 3971-3977, 1997.

12. Aweeka, F.T., Kwong, M., Mak, M., Al-Uzri, A., Affrime, M., **Cutler, D.**, Kahn, J., Gambertoglio, J.G. The pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor: the effects of zidovudine. Journal of Clinical Pharmacology 36:1107-1113, 1996.

13. Pajkrt, D., van der Poll, T., Levi, M., **Cutler, D.L.**, Affrime, M.B., van den Ende, A., Wouter ten Cate, J., van Deventer, S.J.H. Interleukin 10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood 89; 8: 2701-2705, 1997.

14. Huhn, R.D., Radwanski, E., Gallo, J., Affrime, M.B., Sabo, R., Gonyo, G., Monge, A., **Cutler, D.L.** Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers. Clinical Pharmacology and Therapeutics 62, 2: 171-180, 1997.

15. Schenker, S., **Cutler, D.**, Finch, J., Tamburro, C.H., Affrime, M., Sabo, R., Bay, M. Activity and tolerance of a continuous subcutaneous infusion of interferon alfa-2b in patients with chronic hepatitis C. Journal of Interferon Research 17: 665-670, 1997.

16. Nomeir, A., Radwanski, E., **Cutler, D.**, Affrime, M., Christopher, D., Korduba, C., Batra, V., Lin, C., Cayen, M., Single-dose pharmacokinetics of isepamicin in young and geriatric volunteers. Journal of Clinical Pharmacology 37: 1021-1030, 1997.

17. Puren, A.J., Fantuzzi, G., Muhl, H., Shapiro, L., Yoon, D.Y., Hammer, G.R., Affrime, M.B., **Cutler, D.L.**, Dinarello, C.A. The effect of interleukin-10 on whole human blood synthesis of endotoxin-stimulated pro-inflammatory cytokines. Journal of Leukocyte Biology. In review.

18. Anjuin, S., Swan, S.K., Lambrecht, L.J., Radwanski, E., **Cutler, D.L.**, Affrime, M.B., Halstenson, C.E. Pharmacokinetics of flutamide in patients with chronic renal insufficiency. Br J Clin Pharmacol, 47: 43-47, 1999.

19. Radwanski, E., Batra, V., Cayen, M., Korduba, C., **Cutler, D.**, Affrime, M., Nomeir, A., Lin, C.C. Pharmacokinetics of isepamicin following a single administration by intravenous infusion or intramuscular administrations. Antimicrobial Agents and Chemotherapy 41; 1794-1796, 1997.

20. Radwanski,E., Nomeir, A., **Cutler, D.**, Affrime, M., Lin, C.C., Pharmacokinetic Drug Interaction Study: Administration of Ceftibuten Concurrently with the Antacid Mylanta® Double Strength or with Ranitidine. American Journal of Therapeutics 5: 67-72, 1998.

21. Huhn, R.D., Pennline, K., Radwanski, E., Clarke, L., Sabo, R., **Cutler, D.L.** Effects of Single Intravenous Doses of Recombinant Human Interleukin-10 on Subsets of Circulating Leukocytes in Humans. Immunopharmacology 41:109-117, 1999.

22. Anderson, S., et al. Disposition of Recombinant Human Interleukin-10 in Patients with Various Degrees of Renal Function. J Clin Pharmacol 39(10): 1015-1020, 1999.

23. Chakraborty, A., Blum, R., **Cutler, D.L.**, Affrime, M.B., Jusko, W.J. Pharmacokinetic and Adrenal Interactions of IL-10 and Prednisone in Healthy Volunteers. J. Clin. Pharm. 39(6) 624-35, 1999.

24. Chakraborty, A., Blum, R., **Cutler, D.L.**, Jusko, W.J. Pharmacoimmunodynamic Interactions of Interleukin-10 and Prednisone in Healthy Volunteers. Clinical Pharmacology and Therapeutics. 65:304-318, 1999.

26. Reznikov, L L., Puren, A. J., Fantuzzi, G., Muhl, H., Shapiro, L., Yoon, D-Y., **Cutler, D. L.** and Dinarello, C. A. Spontaneous and Inducible Cytokine Responses in Healthy Humans Receiving a Single Dose of IFN-α2b: Increased Production of Interleukin-1 Receptor Antagonist and Suppression of IL-1-Induced IL-8. Journal of Interferon and Cytokine Research 18:897-903, 1998.

27. Baker, S.D., Wirth, M., Statkevich, P., Reidenberg, P., Alton, K., Sartorius, S. E., Dugan, M., **Cutler, D. L.**, Batra, V., Grochow, L. B., Donehower, C., Rowinsky, E. K. Absorption, Metabolism, and Excretion of ^{14}C-Temozolomide Following Oral Administration to Patients with Advanced Cancer. Clinical Cancer Research. 5:309-317, 1999.

28. Radwanski, E., Chakraborty, A., Van Wart, S., Huhn, R. D., **Cutler, D. L.**, Affrime, M.B. and Jusko, W. J. Pharmacokinetics and Leukocyte Responses of Recombinant Human Interleukin-10. Pharmaceutical Research, 15: No. 12; 1895-1901, 1998.

29. Brada, M., Moore, S., Beale, P., Reidenberg, P., Statkevich, P., Dugan, M, Batra, V, **Cutler, D.** Phase I Dose Escalation and Pharmacokinetic Study of Temozolomide (Sch 52365) for Refractory or Relapsing Malignancies. Br. J. Cancer, 81(6)1022-1030, 1999.

30. Beale, P., Judson, I., Moore, S., Statkevich, P., Marco, A., **Cutler, D.L.**, Reidenberg, P., Brada, M. Effect of Gastric pH on the Relative Oral Bioavailability and Pharmacokinetics of Temozolomide. Cancer Chemother Pharmacol , 44:389-394, 1999.

31. Adjei AA, Erlichman C, Davis JN, **Cutler, D.L.**, Sloan JA, Marks RS, Hanson LJ, Svingen PA, Atherton P, Bishop WR, Kirschmeier P, Kaufmann SH. A Phase I trial of the farnesyl transferase inhibitor SCH 66336: evidence for biological and clinical activity. Cancer Res. 2000 Apr 1;60(7):1871-7.

32. Eskens FA, Awada A, **Cutler, D.L.**, de Jonge MJ, Luyten GP, Faber MN, Statkevich P, Sparreboom A, Verweij J, Hanauske AR, Piccart M.. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol. 2001 Feb 15;19(4):167-75.

33. Jen JF, **Cutler, D.L.**, Pai SM, Batra VK, Affrime MB, Zambas DN, Heft S, Hajian G. Population pharmcokinetics of temozolomide in cancer patients. Pharm Res. 2000 Oct;17(10):1284-9.

34. Gorski JC, Hall SD, Becker P, Affrime MB, **Cutler, D.L.**, Haehner-Daniels B. In vivo effects of interleukin-10 on human cytochrome P450 activity. Clin Pharmacol Ther. 2000 Jan;67(1):32-43.

35. Kosoglou, T., Meyer, I., Veltri, E., Statkevich, P., Yang, B., Zhu, Y., Mellars, L., Maxwell, S., Patrick, J., **Cutler, D.**, Batra, V., Affrime, M. Pharmacodynamics interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmcol, 2002 May 14:54, 309-319

36. Jen, J.F., **Cutler, D.**, Pai, S., Affrime, M., Hajian, G., Heft, S. Population Pharmacokinetic Analysis of Temozolomide. In Aarons, L., Balant, L., Danhof, M., et al (eds.). European cooperation in the field of scientific and technical research. The population approach: measuring and managing variability in response, concentration and dose (EUR 17611). Directorate-General Science, Research and Development, European Commission, Brussels, 1997.

37. Bukowski, R., Tendler, C., **Cutler, D.**, Rose, E., Laughlin, M, Statkevich, P. Treating Cancer with PEG Intron – Pharmacokinetic Profile and Dosing Guidelines for an Improved Interferon alfa-2b Formulation. Cancer 95(2): 389-396, 2002.

38. Statkevich P., Kosoglou T., Zhu Y., Maxwell SE, Calzetta A., **Cutler, D.L.**, Patrick JE, Affrime, MB., Batra VK., Effect of gender on the pharmacokinetics of ezetimibe, a novel cholesterol absorption inhibitor. Submitted for publication Nov 2001.

39. Kosoglou,T., Statkevich P., Zhu Y., Boutros T., Soni PP., Maxwell SE., **Cutler DL**, Patrick JE., Batra VK., Affrime MB. Effect of age on the pharmacokinetics of ezetimibe. Submitted for publication Nov 2001.

40. Awada A., Eskens F, Piccart M, **Cutler DL**, van der Gaast A, Bleiberg H, Wanders J, Faber MN, Statkevich P, Fumoleau P and Verweij J. Phase I and Pharmacological Study of the Oral Farnesyltransferase Inhibitor SCH 66336 Given Once Daily to Patients with Advanced Solid Tumors. Eur Cancer 38 (17) 2272-2278, 2002.

41. Rudek MA, Donehower RC, Statkevich P, Batra VK, **Cutler DL**, Baker SD. Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study. Pharmacotherapy 2004;24(1): 16-25.

42. Kosoglou T, Stakevich P, Meyer I, **Cutler DL**. Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin. Current Medical Research and Opinion 2004;20(6): 955-965.

43. Grace M, **Cutler DL**. PEGylated interferons for chronic hepatitis C: an update. Expert Opinion in Drug Delivery.

BOOK CHAPTERS

1. Chernoff, A.E., Granowitz, E.V., Shapiro, L., Vannier, E., Lonnemann, G., Angel, J.B., Orencole, S.F., Kennedy, J.S., Zhang, X.X., Wen, H.D., Donaldson, E.C., Radwanski, E., **Cutler, D.L.**, Wolff, S.M., Dinarello, C.A. A Phase I study of interleukin-10 in healthy humans: safety and effects on cytokine production. In Molecular Biology Intelligence Unit Interleukin-10, Landes Publishing Company, 1995.

2. **Cutler, D.L.**: Pharmacology of Interferon. In: Arroyo, V., Bosch, J., Rodis, J., (eds) Treatments in hepatology, Masson, S.A., 1995.

INVITED LECTURES

1. Canadian Association of Pharmaceutical Regulatory Affairs (CAPRA)/Drugs Directorate Symposium on Biotechnology Issues: Industry and Drugs Directorate Perspectives October 23-25, 1995; Ottawa, Ontario, Canada. Issues in Phase I Trials of Biologics.

2. International Symposium on Treatments in Hepatology March 15-17, 1995; Barcelona, Spain. Pharmacology of Interferon.

3. American Society for Clinical Pharmacology and Therapeutics Rheumatology, Immunology and Inflammation Section Meeting March 6, 1997; San Diego, California. Pharmacology of rHuIL-10.

4. 4th International Congress on The Immune Consequences of Trauma, Shock and Sepsis, March 4, 1997; Munich, Germany. Multiple-Dose Pharmacology of rHuIL-10.